Brokerages expect Danaher Corporation (NYSE:DHR) to announce earnings of $0.95 per share for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for Danaher Corporation’s earnings, with the lowest EPS estimate coming in at $0.94 and the highest estimate coming in at $0.96. Danaher Corporation reported earnings of $0.87 per share in the same quarter last year, which indicates a positive year over year growth rate of 9.2%. The business is scheduled to issue its next earnings results on Thursday, October 19th.
According to Zacks, analysts expect that Danaher Corporation will report full-year earnings of $3.95 per share for the current financial year, with EPS estimates ranging from $3.91 to $3.96. For the next year, analysts forecast that the company will post earnings of $4.27 per share, with EPS estimates ranging from $4.20 to $4.35. Zacks’ EPS averages are an average based on a survey of analysts that cover Danaher Corporation.
Danaher Corporation (NYSE:DHR) last posted its quarterly earnings data on Thursday, July 20th. The conglomerate reported $0.99 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.02. Danaher Corporation had a net margin of 12.63% and a return on equity of 11.15%. The business had revenue of $4.51 billion during the quarter, compared to analysts’ expectations of $4.50 billion. During the same quarter in the prior year, the business posted $0.90 earnings per share. Danaher Corporation’s revenue was up 6.3% compared to the same quarter last year.
DHR has been the subject of several analyst reports. Janney Montgomery Scott downgraded Danaher Corporation from a “buy” rating to a “neutral” rating in a research note on Wednesday, June 7th. BidaskClub downgraded Danaher Corporation from a “hold” rating to a “sell” rating in a research note on Saturday, July 8th. Wells Fargo & Company restated a “market perform” rating on shares of Danaher Corporation in a research note on Saturday, July 22nd. Citigroup Inc. set a $96.00 target price on Danaher Corporation and gave the stock a “buy” rating in a research note on Friday, July 21st. Finally, Zacks Investment Research downgraded Danaher Corporation from a “hold” rating to a “sell” rating in a research note on Monday, June 19th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $92.72.
In related news, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $81.78, for a total value of $799,154.16. Following the sale, the insider now directly owns 155,520 shares of the company’s stock, valued at $12,718,425.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Linda P. Hefner sold 10,578 shares of the company’s stock in a transaction on Friday, July 21st. The stock was sold at an average price of $83.03, for a total value of $878,291.34. Following the completion of the sale, the director now directly owns 42,151 shares in the company, valued at $3,499,797.53. The disclosure for this sale can be found here. Insiders have sold 71,496 shares of company stock worth $5,916,223 over the last three months. Insiders own 12.20% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. GQG Partners LLC bought a new stake in Danaher Corporation in the second quarter worth $101,000. Peddock Capital Advisors LLC boosted its holdings in Danaher Corporation by 17.4% in the first quarter. Peddock Capital Advisors LLC now owns 1,224 shares of the conglomerate’s stock worth $105,000 after acquiring an additional 181 shares in the last quarter. Proficio Capital Partners LLC boosted its holdings in Danaher Corporation by 92.3% in the first quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock worth $105,000 after acquiring an additional 598 shares in the last quarter. Monetary Management Group Inc. boosted its holdings in Danaher Corporation by 10.7% in the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after acquiring an additional 150 shares in the last quarter. Finally, Acrospire Investment Management LLC boosted its holdings in Danaher Corporation by 185.5% in the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after acquiring an additional 1,100 shares in the last quarter. 75.75% of the stock is currently owned by institutional investors.
Danaher Corporation (NYSE:DHR) traded up 0.23% during midday trading on Tuesday, reaching $87.27. 2,158,100 shares of the company traded hands. Danaher Corporation has a one year low of $75.71 and a one year high of $88.01. The firm has a 50-day moving average price of $81.99 and a 200-day moving average price of $84.14. The firm has a market capitalization of $60.63 billion, a price-to-earnings ratio of 27.86 and a beta of 1.03.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 29th will be paid a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a dividend yield of 0.64%. Danaher Corporation’s dividend payout ratio (DPR) is presently 17.83%.
WARNING: This story was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://sportsperspectives.com/2017/09/12/zacks-brokerages-expect-danaher-corporation-dhr-will-announce-earnings-of-0-95-per-share.html.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.